Academic Journal
Bimodal Release Ondansetron for Acute Gastroenteritis Among Adolescents and Adults: A Randomized Clinical Trial.
| العنوان: | Bimodal Release Ondansetron for Acute Gastroenteritis Among Adolescents and Adults: A Randomized Clinical Trial. |
|---|---|
| المؤلفون: | Silverman, Robert A, House, Stacey L, Meltzer, Andrew C, Hahn, Barry, Lovato, Luis M, Avarello, Jahn, Miller, Joseph B, MD, Kalfus, Ira N, Fathi, Reza, Raday, Gilead, Plasse, Terry F, Yan, Eric C |
| المصدر: | Emergency Medicine Articles |
| بيانات النشر: | Henry Ford Health Scholarly Commons |
| سنة النشر: | 2019 |
| المجموعة: | Henry Ford Health System Scholarly Commons |
| الوصف: | Importance: Vomiting resulting from acute gastroenteritis is commonly treated with intravenous antiemetics in acute care settings. If oral treatment were beneficial, patients might not need intravenous administered hydration or medication. Furthermore, a long-acting treatment could provide sustained relief from nausea and vomiting. Objective: To determine whether an experimental long-acting bimodal release ondansetron tablet decreases gastroenteritis-related vomiting and eliminates the need for intravenous therapy for 24 hours after administration. Design, Setting, and Participants: This placebo-controlled, double-blind, randomized clinical trial included patients from 19 emergency departments and 2 urgent care centers in the United States from December 8, 2014, to February 17, 2017. Patients 12 years and older with at least 2 vomiting episodes from presumed gastroenteritis in the previous 4 hours and symptoms with less than 36 hours' duration were randomized using a 3:2 active to placebo ratio. Analyses were performed on an intent-to-treat basis and conducted from June 1, 2017, to November 1, 2017. Intervention: Bimodal release ondansetron tablet containing 6 mg of immediate release ondansetron and 18 mg of a 24-hour release matrix for a total of 24 mg of ondansetron. Main Outcomes and Measures: Treatment success was defined as no further vomiting, no need for rescue medication, and no intravenous hydration for 24 hours after bimodal release ondansetron administration. Results: Analysis included 321 patients (mean [SD] age, 29.0 [11.1] years; 195 [60.7%] women), with 192 patients in the bimodal release ondansetron group and 129 patients in the placebo group. Treatment successes were observed in 126 patients in the bimodal release ondansetron group (65.6%) compared with 70 patients in the placebo group (54.3%), with an 11.4% (95% CI, 0.3%-22.4%) absolute probability difference. The proportion of treatment success was 21% higher among patients who received bimodal release ondansetron compared with those who ... |
| نوع الوثيقة: | text |
| اللغة: | unknown |
| Relation: | https://scholarlycommons.henryford.com/emergencymedicine_articles/173; http://sfxhosted.exlibrisgroup.com/hfhs?sid=Entrez:PubMed&id=pmid:31702802 |
| الاتاحة: | https://scholarlycommons.henryford.com/emergencymedicine_articles/173 http://sfxhosted.exlibrisgroup.com/hfhs?sid=Entrez:PubMed&id=pmid:31702802 |
| رقم الانضمام: | edsbas.D6F841B1 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |